Preserving the Promise of Cancer Immunotherapy
Rarely does the biopharma industry see anything like the explosion of activity that is immuno-oncology today. There are currently thousands of agents in development, and millions of possible combinations, which need to be tested if we are to successfully treat most cancers. Massive investments are at stake, enormous acquisitions are underway, and there are limited numbers of patients available to participate in trials. How do we keep the promise of immuno-oncology from jumping off the rails?